XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -20.29%801.47M | -32.00%200.88M | -12.03%258.9M | -22.74%186.22M | -11.02%155.47M | -8.05%1.01B | -7.97%295.42M | -3.55%294.3M | -3.86%241.02M | -19.37%174.72M |
Operating revenue | -20.29%801.47M | -32.00%200.88M | -12.03%258.9M | -22.74%186.22M | -11.02%155.47M | -8.05%1.01B | -7.97%295.42M | -3.55%294.3M | -3.86%241.02M | -19.37%174.72M |
Cost of revenue | -22.25%530.18M | -32.49%131.18M | -16.51%167.05M | -21.62%129.51M | -16.19%102.43M | -0.70%681.89M | -10.33%194.33M | 5.82%200.1M | 6.83%165.25M | -3.18%122.22M |
Gross profit | -16.16%271.3M | -31.05%69.7M | -2.50%91.85M | -25.16%56.71M | 1.02%53.04M | -20.46%323.57M | -3.08%101.1M | -18.82%94.2M | -21.07%75.77M | -41.97%52.5M |
Operating expense | 2.07%406.33M | -0.65%108.8M | 1.33%99.3M | 3.58%101.79M | 0.32%92.6M | 8.27%398.07M | 6.75%109.51M | 6.96%97.99M | 7.66%98.27M | 12.32%92.31M |
Selling and administrative expenses | -5.14%220.43M | -10.43%58.78M | -2.33%54.97M | -2.67%54.86M | -11.33%47.99M | 2.02%232.39M | -1.42%65.62M | 1.28%56.28M | 2.38%56.36M | 7.00%54.12M |
-Selling and marketing expense | -0.05%160.64M | -9.79%43.45M | -1.13%38.69M | 3.57%38.89M | -8.42%32.85M | 1.30%160.71M | -1.85%48.17M | -0.33%39.13M | 1.04%37.55M | 8.16%35.87M |
-General and administrative expense | -16.57%59.8M | -12.18%15.33M | -5.07%16.28M | -15.14%15.97M | -17.06%15.14M | 3.70%71.67M | -0.22%17.45M | 5.14%17.15M | 5.15%18.82M | 4.79%18.25M |
Research and development costs | 12.20%185.9M | 13.97%50.03M | 6.28%44.33M | 12.00%46.93M | 16.83%44.61M | 18.45%165.69M | 21.83%43.89M | 15.72%41.71M | 15.70%41.9M | 20.85%38.19M |
Operating profit | -81.25%-135.03M | -364.70%-39.1M | -96.78%-7.45M | -100.40%-45.08M | 0.61%-39.56M | -290.20%-74.5M | -590.90%-8.41M | -115.50%-3.79M | -575.46%-22.49M | -579.81%-39.81M |
Net non-operating interest income expense | 29.16%-3.33M | 14.48%-1.06M | 31.00%-808K | 30.64%-790K | 41.54%-674K | 24.72%-4.7M | 5.65%-1.24M | 1.18%-1.17M | 25.94%-1.14M | 47.80%-1.15M |
Non-operating interest expense | -29.16%3.33M | -14.48%1.06M | -31.00%808K | -30.64%790K | -41.54%674K | -24.72%4.7M | -5.65%1.24M | -1.18%1.17M | -25.94%1.14M | -47.80%1.15M |
Other net income (expense) | -54.01%5.27M | -86.73%563K | 8.61%2.13M | -125.59%-620K | -122.64%-642K | 651.38%11.47M | 88.12%4.24M | 583.97%1.96M | 529.61%2.42M | 726.05%2.84M |
Special income (charges) | ---- | ---- | ---559K | ---1.43M | -20,455.56%-1.85M | -350.00%-963K | -13,528.57%-954K | --0 | --0 | 93.28%-9K |
-Less:Restructuring and merger&acquisition | ---- | ---- | --559K | --1.43M | 20,455.56%1.85M | 350.00%963K | 13,528.57%954K | --0 | --0 | -93.28%9K |
Other non- operating income (expenses) | -57.58%5.27M | -89.17%563K | 37.09%2.69M | -66.53%811K | -57.54%1.21M | 614.31%12.43M | 129.70%5.2M | 591.20%1.96M | 596.52%2.42M | 991.85%2.85M |
Income before tax | -96.49%-133.09M | -632.41%-39.59M | -104.61%-6.13M | -119.18%-46.49M | -7.23%-40.88M | -296.60%-67.73M | -303.23%-5.41M | -112.73%-3M | -906.77%-21.21M | -776.64%-38.12M |
Income tax | 2,156.51%299.22M | 19.58%-2.4M | 202.32%2.08M | 133.34%1.33M | 3,713.34%298.21M | -359.54%-14.55M | -623.49%-2.99M | -88.44%689K | -3,734.55%-4M | -16,082.35%-8.25M |
Net income | -712.87%-432.31M | -1,438.09%-37.19M | -122.88%-8.21M | -177.84%-47.82M | -1,035.25%-339.09M | -284.36%-53.18M | -178.69%-2.42M | -120.97%-3.68M | -783.29%-17.21M | -625.40%-29.87M |
Net income continuous Operations | -712.87%-432.31M | -1,438.09%-37.19M | -122.88%-8.21M | -177.84%-47.82M | -1,035.25%-339.09M | -284.36%-53.18M | -178.69%-2.42M | -120.97%-3.68M | -783.29%-17.21M | -625.40%-29.87M |
Minority interest income | ||||||||||
Net income attributable to the parent company | -712.87%-432.31M | -1,438.09%-37.19M | -122.88%-8.21M | -177.84%-47.82M | -1,035.25%-339.09M | -284.36%-53.18M | -178.69%-2.42M | -120.97%-3.68M | -783.29%-17.21M | -625.40%-29.87M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -712.87%-432.31M | -1,438.09%-37.19M | -122.88%-8.21M | -177.84%-47.82M | -1,035.25%-339.09M | -284.36%-53.18M | -178.69%-2.42M | -120.97%-3.68M | -783.29%-17.21M | -625.40%-29.87M |
Basic earnings per share | -705.71%-2.82 | -1,100.00%-0.24 | -150.00%-0.05 | -181.82%-0.31 | -1,078.95%-2.24 | -294.44%-0.35 | -200.00%-0.02 | -118.18%-0.02 | -650.00%-0.11 | -575.00%-0.19 |
Diluted earnings per share | -705.71%-2.82 | -1,100.00%-0.24 | -150.00%-0.05 | -181.82%-0.31 | -1,078.95%-2.24 | -294.44%-0.35 | -200.00%-0.02 | -120.00%-0.02 | -650.00%-0.11 | -575.00%-0.19 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |